Newsroom

Sorted by: Latest

-

Board of Directors of The Coca-Cola Company Elects Two New Officers and Declares Regular Quarterly Dividend

ATLANTA--(BUSINESS WIRE)--The Board of Directors of The Coca-Cola Company today announced the election of two new company officers and the approval of the company’s regular quarterly dividend. Sedef Salingan Sahin, who began a new role as Chief Digital Officer of the company March 31, was elected by the board as an executive vice president of the company. For more about Sahin’s leadership of the digital transformation of the company, see the company’s press release from January at https://www.c...
-

Inszone Insurance Services Acquires Historic Mena Insurance Agency, Expanding Presence in Arkansas

SACRAMENTO, Calif.--(BUSINESS WIRE)--Inszone Insurance Services, a rapidly growing national provider of commercial, personal, and benefits insurance, is pleased to announce the acquisition of Mena Insurance Agency, Inc., commonly known as Mena Insurance. This strategic acquisition brings a century-old institution and a highly efficient, deeply experienced team into the Inszone organization, further expanding its footprint in Arkansas. Founded in 1911 by H.G. McLafferty, Mena Insurance has been...
-

SentinelOne Unveils Wayfinder Frontier AI Services to Proactively Expose, Prioritize, and Break Real-World Exploitation Chains

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--SentinelOne launches Wayfinder Frontier AI Services with Anthropic's Claude to find and fix real-world exploits across the full attack surface....
-

La Comisión Europea (CE) aprueba POHERDY® (pertuzumab) de Henlius y Organon, el primer biosimilar de PERJETA (pertuzumab) autorizado en Europa

SHANGHÁI, China, y JERSEY CITY, Nueva Jersey--(BUSINESS WIRE)--Shanghai Henlius Biotech, Inc. (2696.HK) y Organon (NYSE: OGN) han anunciado hoy que la Comisión Europea (CE) ha concedido la autorización de comercialización de POHERDY®(pertuzumab), una solución inyectable intravenosa de 420 mg/14 ml, el primer y único biosimilar de PERJETA (pertuzumab) aprobado en Europa, para todas las indicaciones del medicamento de referencia.1 «Al ser el primer biosimilar de pertuzumab, y actualmente el único...
-

OpenAI and Yubico Partner to Bring Custom Phishing-Resistant YubiKeys to OpenAI Users

SANTA CLARA, Calif. & STOCKHOLM--(BUSINESS WIRE)--Regulatory News: Yubico (NASDAQ STOCKHOLM: YUBICO), the pioneer of phishing-resistant authentication and creator of the YubiKey, the gold standard of security keys, today announced an industry-first collaboration with OpenAI, the creator of ChatGPT. Beginning today, people can purchase a new 2-pack set of custom YubiKeys as part of OpenAI’s Advanced Account Security program – enabling them to secure their ChatGPT accounts with security keys, con...
-

OpenAI och Yubico inleder samarbete för att erbjuda skräddarsydda YubiKeys med skydd mot nätfiske

SANTA CLARA, Kalifornien och STOCKHOLM, Sverige--(BUSINESS WIRE)--Regulatory News: Yubico (NASDAQ STOCKHOLM: YUBICO), pionjär inom nätfiskeresistent autentisering och skaparen av YubiKey, guldstandarden för säkerhetsnycklar, meddelar idag ett branschledande samarbete med OpenAI, skaparen av ChatGPT. Från och med idag kan OpenAI:s användare köpa ett tvåpack med specialdesignade YubiKeys inom ramen för OpenAI:s program för avancerad kontosäkerhet (Advanced Account Security program). Det gör det m...
-

La Commissione Europea (CE) approva POHERDY® (pertuzumab), messo a punto da Henlius e Organon, il primo biosimilare di PERJETA (pertuzumab) approvato in Europa

SHANGHAI, Cina e JERSEY CITY, N.J.--(BUSINESS WIRE)--Shanghai Henlius Biotech, Inc. (2696.HK), e Organon (NYSE: OGN) oggi hanno annunciato che la Commissione Europea (CE) ha concesso l'autorizzazione all'immissione in commercio per POHERDY® (pertuzumab) 420 mg/14 mL iniezione per uso endovenoso, il primo e unico biosimilare di PERJETA (pertuzumab) approvato in Europa, per tutte le indicazioni del prodotto di riferimento.1 “In quanto primo e attualmente unico biosimilare del pertuzumab in Europe...
-

Europäische Kommission erteilt Marktzulassung für POHERDY® (Pertuzumab) von Henlius und Organon, das erste in Europa zugelassene Biosimilar zu PERJETA (Pertuzumab)

SHANGHAI, China, und JERSEY CITY, New Jersey, USA--(BUSINESS WIRE)--Shanghai Henlius Biotech, Inc. (2696.HK) und Organon (NYSE: OGN) gaben heute bekannt, dass die Europäische Kommission die Zulassung für POHERDY® (Pertuzumab) 420 mg/14 ml Injektion zur intravenösen Verabreichung erteilt hat. Damit ist POHERDY das erste und einzige in Europa zugelassene Biosimilar zu PERJETA (Pertuzumab) für alle Indikationen des Referenzprodukts.1 „Als erstes und derzeit einziges Pertuzumab-Biosimilar in Europa...
-

Northfield Bancorp Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Northfield Bancorp, Inc. - NFBK

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Northfield Bancorp, Inc. (NasdaqGS: NFBK) and Columbia Financial, Inc. (NasdaqGS: CLBK). Under the terms of the proposed transaction, each Northfield share will be converted into either stock or cash, at the holder’s election, with consideration tied to the final independent valuation: from 1.425–1.465 holdi...
-

OpenAI und Yubico schließen Partnerschaft, um OpenAI-Nutzern maßgeschneiderte, Phishing-resistente YubiKeys anzubieten

SANTA CLARA, Kalifornien, und STOCKHOLM, Schweden--(BUSINESS WIRE)--Yubico (NASDAQ STOCKHOLM: YUBICO), der Pionier der Phishing-resistenten Authentifizierung und Entwickler des YubiKey, dem Goldstandard unter den Sicherheitsschlüsseln, gab heute eine branchenweit einzigartige Zusammenarbeit mit OpenAI, dem Entwickler von ChatGPT, bekannt. Ab heute können Nutzer im Rahmen des „Advanced Account Security“-Programms von OpenAI ein neues 2er-Set maßgeschneiderter YubiKeys erwerben, mit denen sie ihr...